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The flavors of vitamin D: Tasting the molecular mechanisms
For many years, vitamin D has been the definitive ther-
apeutic intervention for secondary hyperparathyroidism
in patients with chronic kidney disease (CKD), particu-
larly for those undergoing dialysis [1]. Vitamin D sterols
reduce parathyroid hormone (PTH) synthesis, and lower
plasma PTH levels in such patients by inhibiting PTH
gene transcription in parathyroid tissue. These biological
actions require sterol binding to the vitamin D receptor
(VDR) and translocation of the ligand-receptor complex
to the cell nucleus. Here, the ligand-bound VDR forms a
heterodimer with the retenoid X receptor (RXR), and
this complex interacts with a vitamin D response ele-
ment (VDRE) in the promoter region to negatively regu-
late pre-pro-PTH gene transcription. The same genomic
mechanism of action influences the expression of a va-
riety of vitamin D–regulated proteins in other tissues,
including intestine and kidney. Unfortunately, the bio-
logical actions of vitamin D in these target tissues often
lead to treatment-related side effects [1].
The doses of vitamin D required to down-regulate
PTH gene expression and to lower plasma PTH levels in
patients with CKD are usually sufficient to enhance ex-
pression of certain proteins, such as the calbindins, which
facilitate calcium transport in intestinal epithelia. As a
result, net intestinal calcium absorption rises, leading to
increases in serum calcium concentrations and/or to overt
hypercalcemia, a major dose-limiting side effect of virtu-
ally all vitamin D sterols. The therapeutic index for most
vitamin D analogs is thus rather narrow when used clini-
cally to manage secondary hyperparathyroidism [1].
Apart from the calbindins, recent observations indi-
cate that vitamin D affects the expression of two impor-
tant members of the vanilloid subfamily (TRPV) that
is part of the superfamily of transient receptor poten-
tial (TRP) proteins. Two highly homologous members,
TRPV5 and TRPV6, are expressed predominantly in
calcium-transporting epithelia and play pivotal roles in
the transepithelial movement of calcium in kidney and
intestine [2]. TRPV5 is synonymous with the epithelial
calcium channel (ECaC1) that was cloned originally from
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epithelial cells derived from rabbit kidney and identi-
fied subsequently in other species [3–5]. TRPV6 corre-
sponds to the epithelial calcium channel (ECaC2) that
was cloned initially from rat duodenum [6] and also char-
acterized both in human and murine tissues. TRPV5 and
TRPV6 are constitutively activated calcium channels that
mediate calcium entry across the apical membrane of re-
nal tubular and intestinal epithelial cells, respectively [2].
They most probably represent the rate-limiting step in
the transepithelial movement of calcium in both tissues
[7]. Calcitriol, or 1,25-dihydroxyvitamin D, up-regulates
the expression of both TRPV5 and TRPV6, and four pu-
tative VDREs have been identified in the TRPV5 pro-
moter. In duodenum, TRPV6 expression, and to a lesser
extent TRPV5 expression, is enhanced by dietary calcium
supplementation through vitamin D–independent mech-
anisms [2]. These observations suggest additional mech-
anisms that may account for alterations in renal tubular
calcium transport and in intestinal calcium absorption in
CKD. They also provide an opportunity to examine more
carefully how disturbances in vitamin D metabolism af-
fect these processes and to explore mechanisms to explain
differences among the vitamin D sterols with respect to
their impact on calcium metabolism.
In the current issue of Kidney International, Hoen-
derop et al [8] explore these issues in studies uti-
lizing mice homozygous for inactivating mutations of
the renal 25-hydroxyvitamin D3-1a-hydroxylase en-
zyme, or 1aOHase−/− mice. These animals serve as a
murine model of the clinical disorder of pseudo-vitamin
D–deficient rickets (PDDR), in which the capacity to
synthesize 1,25-dihydroxyvitamin D3, the most potent
metabolite of vitamin D, is disrupted [9]. Affected mice
exhibit growth retardation with rickets and osteoma-
lacia. Biochemical abnormalities include hypocalcemia,
markedly elevated plasma PTH levels due to severe sec-
ondary hyperparathyroidism, hypophosphatemia from
PTH-mediated increases in renal phosphorus excre-
tion, and undetectable plasma calcitriol levels [9]. The
1aOHase−/− mouse thus provides a useful experimen-
tal model for assessing the impact of any of a number
of vitamin D sterols on the expression of various vita-
min D–regulated proteins without confounding effects
due to changes in endogenous 1-25, dihydroxyvitamin D3
production.
Single doses of three different vitamin D analogs were
given to separate groups of 1aOHase−/− mice. The com-
pounds evaluated included 1,25-dihydroxyvitamin D3,
1286
Editorial 1287
1,24-dihydroxyvitamin D2, and 1a(OH)D2, or doxercal-
ciferol, 100 ng/animal for each agent [8]. Serum cal-
cium concentrations were measured at specified intervals
during the 96 hours immediately after vitamin D ad-
ministration. The levels of expression of several proteins
including TRPV5 and TRPV6, calbindin-D9k, calbindin-
D28k, and both the high affinity Ca+2-ATPase (PMCA1)
and the Na+-Ca+2 exchanger (NCX1), which are local-
ized to the basolateral membrane and serve to extrude
calcium from the cell, were measured in kidney and in-
testine. Protein levels were assessed by semiquantitative
methods using immunohistochemistry and image analy-
sis, whereas mRNA expression was determined by real-
time polymerase chain reaction (PCR) [8].
Serum calcium concentrations increased in
1aOHase−/−mice after the administration of each
vitamin D sterol. The time course of the change in serum
calcium concentration in each group largely reflected
differences in the pharmacokinetics of each compound.
Increases in serum calcium levels occurred substantially
later in animals given 1a(OH)D2, which requires 25-
hydroxylation in the liver to form the active metabolite
1,25-dihydroxy-vitamin D2. Temporal changes in mRNA
expression for TRPV5 and TRPV6 in intestine and
kidney also differed among vitamin D analogs, with
increases occurring earlier in mice given either 1,25-
dihydroxyvitamin D3 or 1,24-dihydroxy-vitamin D2 but
somewhat later in animals given 1a(OH)D2 [8].
Although preliminary in nature, the results provide po-
tentially important insights into mechanisms that could
account for variations in the biochemical response to
treatment with different analogs of vitamin D. The ef-
fort to identify analogs of vitamin D that effectively
inhibit PTH gene transcription in parathyroid tissue with-
out promoting intestinal calcium absorption has been
considerable. This goal has yet to be achieved, but com-
pounds such as 19-nor-1,25-dihydroxyvitamin D2, pari-
calcitol, and 1a(OH)D2, or doxercalciferol, have been
shown to be less potent than calcitriol in raising serum cal-
cium levels in selected experimental models. Both agents
are now available for use clinically, and one report sug-
gests that the use of paricalcitol is associated with fewer
episodes of hypercalcemia compared with calcitriol dur-
ing the treatment of secondary hyperparathyroidism in
patients undergoing hemodialysis [10].
Until recently, our understanding of the mechanisms
that explain the divergent biological actions of different
vitamin D sterols was quite limited. The investigational
approach employed by Hoenderop et al and presented
in the current issue should substantially advance knowl-
edge in this area and define more precisely the molecular
mechanisms responsible for such differences.
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